Jade Howard, Nourine A H Kamili, Hala Idris, Loren D Krueger
{"title":"公众对斑秃Janus激酶（JAK） i抑制剂的兴趣：趋势分析。","authors":"Jade Howard, Nourine A H Kamili, Hala Idris, Loren D Krueger","doi":"10.2196/75119","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong>Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e75119"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108956/pdf/","citationCount":"0","resultStr":"{\"title\":\"Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis.\",\"authors\":\"Jade Howard, Nourine A H Kamili, Hala Idris, Loren D Krueger\",\"doi\":\"10.2196/75119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Unlabelled: </strong>Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.</p>\",\"PeriodicalId\":73553,\"journal\":{\"name\":\"JMIR dermatology\",\"volume\":\"9 \",\"pages\":\"e75119\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2026-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108956/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JMIR dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2196/75119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/75119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis.
Unlabelled: Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
